| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5485827 | MALLINCKRODT HOSP | Methods and devices for treating plumonary vasoconstriction and asthma |
Jan, 2013
(11 years ago) | |
| US5873359 | MALLINCKRODT HOSP | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jan, 2013
(11 years ago) | |
|
US5873359 (Pediatric) | MALLINCKRODT HOSP | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jul, 2013
(10 years ago) | |
|
US5485827 (Pediatric) | MALLINCKRODT HOSP | Methods and devices for treating plumonary vasoconstriction and asthma |
Jul, 2013
(10 years ago) | |
| US5558083 | MALLINCKRODT HOSP | Nitric oxide delivery system |
Nov, 2013
(10 years ago) | |
|
US5558083 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery system |
May, 2014
(9 years ago) | |
| US5752504 | MALLINCKRODT HOSP | System for monitoring therapy during calibration |
Dec, 2016
(7 years ago) | |
| US5732693 | MALLINCKRODT HOSP | Pause control of nitric oxide therapy |
Dec, 2016
(7 years ago) | |
| US6125846 | MALLINCKRODT HOSP | Purge system for nitric oxide administration apparatus |
May, 2017
(6 years ago) | |
|
US5752504 (Pediatric) | MALLINCKRODT HOSP | System for monitoring therapy during calibration |
Jun, 2017
(6 years ago) | |
|
US5732693 (Pediatric) | MALLINCKRODT HOSP | Pause control of nitric oxide therapy |
Jun, 2017
(6 years ago) | |
|
US6125846 (Pediatric) | MALLINCKRODT HOSP | Purge system for nitric oxide administration apparatus |
Nov, 2017
(6 years ago) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(5 years from now) | |
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(5 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(5 years from now) | |
|
US8795741 (Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(5 years from now) | |
|
US8846112 (Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(5 years from now) | |
|
US8282966 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(5 years from now) | |
|
US8293284 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(5 years from now) | |
|
US8431163 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(5 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
|
US8291904 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US9408993 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US8776795 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8776794 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US9265911 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8573209 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8573210 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US9295802 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
| US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(9 years from now) | |
|
US9279794 (Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(10 years from now) | |
| US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(12 years from now) | |
|
US9770570 (Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(12 years from now) | |
Inomax is owned by Mallinckrodt Hosp.
Inomax contains Nitric Oxide.
Inomax has a total of 42 drug patents out of which 12 drug patents have expired.
Expired drug patents of Inomax are:
- US5485827
- US5873359
- US5873359*PED
- US5485827*PED
- US5558083
- US5558083*PED
- US5752504
- US5732693
- US6125846
- US5752504*PED
- US5732693*PED
- US6125846*PED
Inomax was authorised for market use on 23 December, 1999.
Inomax is available in gas;inhalation dosage forms.
Inomax can be used as a method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient, a method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide, a method of providing a predetermined concentration of nitric oxide to a patient, a method of purging a nitric oxide delivery system, a method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient, prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide with an oxygen containing gas, a method of providing nitric oxide therapy to a patient, a method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient, a method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitric oxide as compared to the desired delivery concentration of nitric oxide.
The generics of Inomax are possible to be released after 03 November, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-167) | Oct 09, 2018 |
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: Prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide with an oxygen containing gas; A method of providing a predetermined concentration of nitric oxide to a patient...
Dosage: GAS;INHALATION
INOMAX family patents
